GoodRx, Criteo $32 million settlement set to be approved by US judge on third try | MLex | Specialist news and analysis on legal risk and regulation
A US judge is set to approve a $32 million settlement for GoodRx and Criteo, resolving privacy allegations. This is the third iteration of the settlement. Both companies are involved in the case.
How this was made
The 30-second read
Why it matters
Resolution of the privacy case removes a legal cloud, but the settlement size is modest relative to both companies' valuations.
Market read
Legal settlement news with limited immediate price impact but relevant for risk assessment in the health‑tech and ad‑tech sectors.
What to watch
Potential future regulatory actions could outweigh the immediate settlement impact.
Background
The article reports a third‑iteration $32 million settlement to resolve privacy allegations against GoodRx and Criteo, pending a U.S. judge's preliminary approval.
Ticker impact
GoodRx is part of a $32 million privacy settlement awaiting preliminary approval.
small upside if settlement is viewed favorably, limited downside risk.
Settlement amount is moderate; market may price in reduced litigation exposure.
Criteo is involved in the same $32 million privacy settlement with GoodRx.
minor positive effect as regulatory uncertainty lifts.
Settlement size is modest relative to Criteo's market cap; impact likely limited.
Market effects
Highlights ongoing privacy enforcement risk for health‑tech and ad‑tech sectors.
U.S. and EU privacy regulators may see increased scrutiny of similar firms.
Sets precedent for cross‑border privacy settlements affecting multinational tech companies.
Counterpoint
Settlement may be seen as a cost without substantive change, limiting price reaction.
Key entities
- CompanyGoodRx
Telemedicine platform facing privacy lawsuit.
- CompanyCriteo
French ad‑tech firm co‑defendant in the settlement.
